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Mutational pathway determines whether drug gradients accelerate evolution of
drug-resistant cells
Philip Greulich∗, Bartłomiej Waclaw,∗ and Rosalind J. Allen
SUPA, School of Physics and Astronomy, University of Edinburgh,
Mayfield Road, Edinburgh EH9 3JZ, United Kingdom
Drug gradients are believed to play an important role in the evolution of bacteria resistant to
antibiotics and tumors resistant to anti-cancer drugs. We use a statistical physics model to study
the evolution of a population of malignant cells exposed to drug gradients, where drug resistance
emerges via a mutational pathway involving multiple mutations. We show that a non-uniform drug
distribution has the potential to accelerate the emergence of resistance when the mutational pathway
involves a long sequence of mutants with increasing resistance, but if the pathway is short or crosses
a fitness valley, the evolution of resistance may actually be slowed down by drug gradients. These
predictions can be verified experimentally, and may help to improve strategies for combatting the
emergence of resistance.
PACS numbers: 02.50.Ey, 05.70.Fh, 05.70.Ln, 64.60.-i
The evolution of drug resistance is an urgent problem
in the treatment of disease, from bacterial infections to
cancer. Attempts to address this problem include the
characterization of mutational pathways leading to resis-
tance [1, 2], as well as theoretical [3–8] and experimen-
tal [9–11] studies of the emergence of resistance under
different treatment regimens. These studies usually as-
sume a spatially uniform drug concentration. However,
in many clinical situations drug concentrations vary in
space [12, 13], for example where malignant cells form
less drug-permeable layers such as bacterial biofilms [14]
or tumour stromas [15]. Recent experimental work [16]
suggests that the evolution of antibiotic resistance in bac-
terial populations can be greatly accelerated if the antibi-
otic concentration is spatially non-uniform.
It is often observed that several mutations are required
to obtain maximal resistance to a drug [1, 2, 16]. In
some cases, fitness (i.e. drug resistance) increases steadily
along the mutational pathway to full resistance [1]; in
other cases, epistatic interactions between mutations may
result in less fit intermediate genotypes (fitness “valleys”)
[17–19]. The role of mutational pathways in controlling
evolutionary dynamics has been studied in the quasis-
pecies model [20, 21] and in models of cancer progression
[22, 23]. That work does not take into account the ef-
fects of spatial inhomogeneity. In models without com-
plex evolutionary pathways, it is well known that spatial
structure can increase genetic diversity, the rate of evolu-
tionary diversification [24–28], and the rate of viral drug
resistance [29]; indeed, in a broader statistical physics
context, spatial structure plays a key role in many theo-
retical studies of evolving populations [24, 30–36].
Here, we present a model that combines evolution
along mutational pathways in genotype space with pop-
ulation dynamics in non-uniform environments. We use
this model to study the evolution of drug resistance as a
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Figure 1: Simulation snapshots for the cases of a uniform
and an exponentially increasing drug concentration (left and
right, respectively). Blue lines show the drug concentration
(left axes), while the colours represent the populations of the
different genotypes (right axes). Parameter values are K =
100, L = 500,M = 6, µ = 5× 10−6, βm = 4
m−1, and the drug
concentration c = 0.3 (left panel) and c(x) = eαx − 1 with
α = 0.012 (right panel). For corresponding movies see [37].
population of cells colonizes an environment containing
a non-uniform distribution of a growth-inhibiting drug.
Our key result is that the effect of drug gradients depends
critically on the pathway to resistance. This is due to a
complex interplay between the spatial drug distribution
and the mutational pathway. In the presence of drug
gradients, the population evolves drug resistance in a se-
quence of waves of increasingly better adapted mutants
that extend its range in a step-wise manner. In contrast,
for a uniformly distributed drug, resistant mutants evolve
at random positions and spread over the entire environ-
ment. If tolerance to the drug increases monotonously
along the mutational pathway, drug gradients can signif-
icantly accelerate the evolution of resistance by increas-
ing selection at the population’s edge. However, if the
pathway crosses a fitness valley, evolution of resistance
may actually be slowed down by a non-uniform drug dis-
tribution, as a result of a reduced rate of “stochastic tun-
nelling” due to a smaller population size.
2The model. We consider a growing population of cells
which mutate betweenM possible genotypes, with differ-
ent levels of resistance to a drug. To model the effects of
spatial heterogeneity, the population is assumed to reside
within a chain of L connected microhabitats, which may
contain different concentrations of the drug. These dis-
crete microhabitats might represent connected chambers
in a microfluidic experiment [16]; in the limit of small
microhabitats, our model represents a population grow-
ing in continuous space. Within a given microhabitat i
the population is assumed to be well-mixed, with a fixed
carrying capacityK; cells of genotype m replicate at rate
φm(ci)(1−Ni/K) whereNi is the total population of cells
in microhabitat i, ci is the drug concentration and φm(ci)
is the growth rate of genotype m, which depends on the
local drug concentration. Upon replication, cells mutate
with probability µ; we consider the case of an unbranched
mutational pathway to drug resistance, such that geno-
type m mutates only into genotypes m± 1 (without any
bias). Cells migrate between microhabitats i and i± 1 at
rate b/2 and die at a fixed rate d; the latter ensures that
in the steady state there is a turnover of cells, with the
net birth rate being equal to the death rate d.
A key feature of our model is the fact that different
genotypes show different levels of drug resistance: geno-
type 1 is least resistant while genotype M is most re-
sistant. For all genotypes, the growth rate decreases
with the drug concentration; the minimal inhibitory
concentration (MIC), βm, denotes the drug concentra-
tion at which genotype m ceases to be able to grow.
This is embodied in our model by setting φm(c) =
max
{
0, 1− (c/βm)
2
}
. This choice is inspired by Ref.
[38] (see also the supplementary text [39], Sec. I).
We study this model using kinetic Monte Carlo simula-
tions ([39], Sec. II) which are initiated with N1 = K cells
of genotype 1 in microhabitat 1 and with all the other mi-
crohabitats empty, so that the population colonizes the
space during the simulation, as it evolves resistance to the
drug. We define the units of time by fixing the maximal
growth rate φm(0) = 1 and the units of drug concentra-
tion by fixing β1 = 1, and we set b = 0.1, d = 0.1, and
K = 100. We use values of µ and L such that the num-
ber of mutants per generation emerging anywhere in the
environment is typically small, µKL ≤ 1, and stochastic
effects are relevant. A detailed discussion of the param-
eter set is given in the supplementary text [39], Sec. I.
To investigate the effects of the spatial distribution of
the drug, we consider two scenarios: i) a non-uniform
drug concentration ci = exp(αi)− 1, which increases ex-
ponentially from left to right with steepness α, and ii) a
uniform drug concentration ci ≡ c. Note that we have
not chosen to keep the total amount of drug constant.
Rather, we allow the parameters α and c to vary over
their whole range, and determine whether, under any cir-
cumstances (i.e. for any values of α and c), it is possible
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Figure 2: Average time to resistance τ¯ for uniform ((a,d),
red circles) and non-uniform ((b,e), blue circles) drug concen-
trations, for M = 6, L = 500, K = 100, and µ = 5 × 10−6.
Panels (a,b): exponentially increasing MIC (shown in c), pan-
els (d,e): fitness valley (shown in f). For the non-uniform case
(b,e), the red dashed lines show the minimal value of τ¯ ob-
tained for the uniform case (i.e. the minimum of τ¯(c) from
(a,d)). The black lines show the theoretical predictions: (a):
τ¯ ≈ 126642/c3/2 (see also Eq. (IV.11) from Supp. Mat. [39],
Sec. IV), (b): Eq. (3), (d): Eq. (4), and (e): Eq. (5). The
insets show simulation snapshots taken just before the first
occurrence of genotype m = 6, for two values of α (indicated
by arrows).
for resistance to evolve faster in the non-uniform envi-
ronment. In the non-uniform case, we vary α, the only
constraint being that the drug concentration c1 in the
first microhabitat must be lower than β1, to allow the
first genotype to establish. In the uniform case, we vary
the drug concentration c; the same condition implies that
c ≤ β1, otherwise the space cannot be colonized and no
mutants can emerge. Obviously, the local drug concen-
tration can be much higher in the non-uniform than the
uniform environment. Indeed, one of the results of our
model is that spatial gradients can allow colonization of
regions of much higher drug concentration than would be
possible in a uniform drug environment.
Monotonically increasing MIC. The mutational path-
way to drug resistance plays a crucial role in our simula-
tions. We first consider a pathway to resistance for which
theM genotypes have increasing levels of drug resistance
– i.e. βm > βm−1 for all m > 1, as depicted in Fig. 2c.
In particular, we set M = 6 and βm = 4
m−1; the ratio
β6/β1 ≈ 10
3 between fully resistant and wild-type cells
is consistent with experimentally determined values [1].
Our simulations show that the emergence of drug resis-
tance occurs very differently in the cases of uniform and
non-uniform drug distribution, as illustrated in the snap-
shots of Fig. 1 and in the supplementary movies [37]. If
3the drug concentration is spatially uniform (Fig. 1 left),
genotype 1 (blue) first spreads to fill the entire space,
then mutants of genotype 2 (green) emerge at random
locations and spread to fill the space (competing with
cells of genotype 1) before giving rise to more resistant
mutants of genotype 3, etc. In contrast, in the presence
of a drug gradient (Fig. 1 right), population waves of in-
creasingly better-adapted mutants advance from left to
right in a step-wise manner. Genotype m colonizes the
space only up to a well-defined spatial boundary, where it
forms a stationary “front”; better-adapted mutants then
emerge from this front to further colonize the space.
Thus the spatial gradient generates local “niches” with
low drug concentrations, in which less resistant genotypes
can dwell, generating more resistant mutants, which can
then colonize regions with higher drug concentrations.
These differences have important consequences for the
time to emergence of drug resistance. Fig. 2a and b shows
the mean time τ¯ to emergence of full drug resistance –
i.e. the time to emergence of a mutant with m = M = 6,
averaged over surviving populations. For a uniform drug
concentration ci = c, τ¯ decreases as the drug concentra-
tion c increases (note that c = 1 corresponds to the MIC
of genotype 1) (Fig. 2a). For the non-uniform drug distri-
bution (Fig. 2b), τ¯ varies non-monotonically as a function
of the steepness α, with a minimum at α ≈ 0.01. This
arises because for very small α the selection pressure for
the evolution of resistant mutants is low (since little drug
is present), whereas for very large α, the fronts become
narrow, reducing the size of the “zone” in which new re-
sistant mutants can emerge (see snapshots in Fig. 2b).
Importantly, for almost all values of α and c in Fig. 2,
resistance emerges faster for the non-uniform drug dis-
tribution than for the uniform case; the minimal value
of τ(α) in the non-uniform case is smaller by an order of
magnitude than the minimal value of τ(c) in the uniform
case (dashed line in Fig. 2b). This can be understood
intuitively as follows. For the uniform drug distribution,
a new genotype m + 1 must compete with the already
established genotype m; selection pressure is weak be-
cause the drug concentration is low (restricted by the
constraint c < β1). In contrast, the non-uniform drug
distribution ensures that for each genotype m, there ex-
ists a spatial location with drug concentration c close to
its MIC βm > β1. At the population’s front, the high
drug concentration imposes maximal selection pressure
for the emergence of the next genotype m + 1, which
then can colonize the adjacent empty space, free from
competition. Thus, if the MIC increases monotonically
along the pathway to resistance, a non-uniform drug dis-
tribution carries the potential for much faster evolution
of drug resistance than is possible if the drug is uniformly
distributed.
This picture depends crucially, however, on the length
of the mutational pathway, as shown in Fig. 3. For
long mutational pathways (large M), resistance indeed
Figure 3: Average time τ¯ to full resistance as a function of the
mutational pathway lengthM for uniform (c = 0.9; triangles)
and non-uniform (α = 0.07; crosses) drug distribution. In
both cases L = 300, K = 100, and µ = 10−4. Solid lines are
theoretical predictions for the non-uniform case (black line,
calculated numerically from Eqs. (2) and (3)) and uniform
case (calculated as explained in the supplementary text [39],
Sec. V).
emerges faster in the non-uniform environment. For short
pathways (M < 4 in our simulations), however, the sit-
uation is reversed; resistance actually emerges faster in
the uniform environment than in the non-uniform one,
despite the fact that the drug concentration is higher in
the latter case. This is because the uniform environment
provides a larger population size from which resistant
mutants can emerge.
Our results can be rationalized using simple physical
arguments. We begin with the case of a non-uniform
drug distribution. In our simulations, the population
wave of genotype m typically reaches a "steady state"
before mutants of genotype m+1 emerge; this is because
the selection pressure is high only at the stationary front
(see the supplementary movies [37]). We therefore con-
sider these two processes separately. In the continuous
approximation (valid for large L and α≪ 1), the expan-
sion of a wave of mutants of genotype m is described by
the Fisher-KPP equation [40]:
∂tNm =
b
2
∂xxNm + φmNm
(
1−
Nm
K
)
− dNm (1)
=
b
2
∂xxNm + (φm − d)Nm
[
1−
φmNm
K(φm − d)
]
,
where x ≡ i, φm ≡ φm(c(x)) and Nm ≡ Nm(x, t) denotes
the population of genotypem. If c(x)≪ βm, φm ≈ 1 and
Eq. (1) describes a Fisher wave propagating with speed
v ≈
√
2b(1− d) [40]. The wave stops when it reaches the
point where c(x) ≈ βm; for small b the stationary solu-
tion of Eq. (1) reads N∗m(x) = K[1− d/φm(c(x))], which
decays to zero at x∗m = (1/α) ln(βm
√
(1− d) + 1). As-
suming that the wave of mutants of genotype m emerges
at x∗m−1 (i.e. at the stationary front of the preceding
wave), the time it takes to reach its stationary state is
then Twavem ≈ (x
∗
m − x
∗
m−1)/v, with T
wave
1 ≈ x
∗
1/v.
Once the stationary population of genotypem is estab-
lished, the waiting time before a new wave of mutants of
4genotype m+1 arises can be expressed for low mutation
rates as the inverse of the total rate at which mutants
establish in the population – i.e., assuming strong selec-
tion:
Tmutm+1 =
[
µ
2
∫ x∗
m
x∗
m−1
N∗m(x)r(x)Pfix(x)dx
]
−1
. (2)
Here µ/2 is the probability to mutate from genotypem to
m+ 1, r(x) ≈ d is the rate of reproduction in the steady
state, and Pfix = (φm+1−φm)/φm+1 is the probability of
fixation of genotype m+1; this is a standard result [41].
The mean total time until the first cell of genotype M
emerges is then
τ¯ ≈
M−1∑
m=1
Twavem +
M−1∑
m=2
Tmutm . (3)
The value of τ¯ calculated from Eqs. (2) and (3) is in
good quantitative agreement with our simulation results
(black line in Fig. 2b). Equation (3) decomposes the time
to resistance into the independent contributions of each
wave of mutants. For our choice of MICs and drug distri-
bution, Tmutm and T
wave
m are approximately independent
of m for large m (see supplementary text [39], Sec. III).
Hence for our model τ¯ grows linearly with the length of
the pathway M as shown in Fig. 3. The scaling changes,
however, for very large M (see [39], Sec. III).
If the drug is uniformly distributed, c(x) = c, a differ-
ent argument applies. Here, new genotypes must com-
pete in an already fully colonized space. The time to
fixation of genotype m + 1 scales with the fitness ad-
vantage as (φm+1 − φm)
−γ , where γ > 0 depends on
whether mutations are rare or frequent (see supplemen-
tary text [39], Sec. IV). Since the drug concentration
is fixed, the selective pressure φm+1 − φm ∝ c
2/42m de-
creases for successive genotypes. The rate-limiting step
in the evolution of resistance is then the fixation of geno-
type M − 1, and, as we show in the supplementary text
[39], Sec. IV, for the parameter set from Fig. 2, we ob-
tain τ¯ ≈ 126642/c3/2. This prediction agrees well with
our simulation results (Fig. 2a). The decrease in selective
pressure with m also leads to a super-linear increase in
τ¯ (M) with M , as shown in Fig. 3. It is a consequence
of this effect that, even though for small M evolution
is faster in the uniform drug distribution, for large M ,
resistance evolves much faster in the drug gradient [45].
Fitness valley. We now contrast these results with the
situation where the pathway to resistance passes through
a "fitness valley" - i.e. one of the intermediate geno-
types m has a lower MIC (is less drug-resistant) than
its neighbouring genotypes m − 1 and m + 1. This sce-
nario can arise due to epistatic interactions between mu-
tations [17, 18], such that two mutations are required
to gain a particular fitness benefit. In our model we
set β3 = 3.5, keeping all the other βm = 4
m−1 as be-
fore, so that β2 > β3 < β4, as depicted in Fig. 2f.
Figure 2d and e shows that the presence of the fitness
valley has a dramatic effect on the time to resistance
in the non-uniform environment: τ¯(α) now rises steeply
with α. Crucially, the shortest time to resistance in the
non-uniform environment is now comparable to that in
the uniform environment, minα(τ(α)) ≈ minc(τ(c)), and
τ(α) > minc(τ(c)) for almost all values of α. Thus, when
the pathway to resistance contains a fitness valley, a non-
uniform drug distribution does not speed up, and may
well slow down the emergence of resistance.
To understand this result, we argue that the rate-
limiting step in the evolutionary process is the “tun-
nelling” through the fitness valley [42]: mutants of geno-
type 4 arise from the population of genotype 2 via short-
lived mutants of genotype 3 which do not reach fixation.
The tunnelling rate τ¯−1 has been calculated for well-
mixed populations in Ref. [42] (Eq. (2) therein). Apply-
ing this result to the case of uniform drug distribution we
obtain τ¯−1 ≈ rN2(µ/2)
2(Pfix/s) where N2 ≈ LK(1− d)
is the population size of genotype 2, s = (φ2 − φ3)/φ2
is the selective advantage of genotype 2 over genotype 3,
Pfix = (φ4 − φ2)/φ2 is the fixation probability of geno-
type 4 and r is the growth rate which in the steady state
equals the death rate d. For our choice of φ(c) and {βm},
this gives
τ¯ ≈ 1.23/(dµ2N2) = 1.23/(dµ
2LK(1− d)), (4)
which is independent of c. Equation (4) is in good agree-
ment with our simulation results (black line in Fig. 2d).
Extending this approach to the non-uniform case, we in-
tegrate over the steady-state population density of geno-
type 2:
τ¯ ≈
1.23
dµ2
[∫ x∗
2
0
N∗2 (x)dx
]
−1
. (5)
This result agrees well with our simulation results for the
non-uniform drug distribution (Fig. 2e). The increase in
τ¯ with the steepness of the drug concentration profile α
occurs because the domain occupied by genotype 2 de-
creases as α increases; the non-uniform drug distribution
decreases the steady state population size of genotype 2,
reducing the pool of cells from which mutants of geno-
type 4 can emerge and slowing down the evolution of
resistance.
Conclusion. Our results show that the mutational
pathway to drug resistance plays a crucial role in de-
termining the effect of a spatial drug distribution on the
time to evolve drug-resistant cells. If fitness (i.e. level of
drug resistance) increases monotonically along the mu-
tational pathway, a non-uniform drug distribution has
the potential to accelerate the evolution of resistance, by
a factor that increases dramatically with the length of
the pathway. In contrast, for short pathways, or those
involving a fitness valley, our results show that a non-
5uniform drug distribution does not speed up the evolu-
tion of resistance – indeed, it may actually slow it down.
We have verified that these conclusions are also valid for
two-dimensional simulations and for more complex drug
distributions [43].
Our predictions can be verified experimentally. Recent
microfluidic experiments by Zhang et al. have shown that
gradients of the antibiotic ciprofloxacin greatly acceler-
ate the emergence of resistance of the bacterium E. coli
[16]. Although the mutational pathway in this case is not
known, our results suggest that it is likely to be mono-
tonic [46]. Furthermore, we predict that repeating the
experiments of Zhang et al. using cefotaxime (mono-
tonic pathway [1]) should produce similar results, but
that for streptomycin, which has a fitness valley [17, 18],
drug gradients should actually slow down the emergence
of resistance. Furthermore, our results may also pave
the way to the development of new experimental meth-
ods, in which the characteristics of unknown mutational
pathways are deduced by measuring the dependence of
the time to resistance on drug concentration and drug
gradient.
Note added in revision. After submission of this
manuscript we became aware of related work [44], which
addresses a similar model to ours, for the case of the
mutational pathway with monotonically increasing MIC.
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